Acquisition of Astex Pharmaceuticals, Inc. by Otsuka Pharmaceutical Co., Ltd. May Not Be in the Best Interests of Astex Pharmaceuticals, Inc. Shareholders

Robbins LLP is investigating the acquisition of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex") by Otsuka Pharmaceutical Co., Ltd. ("Otsuka").  On September 5, 2013, the two companies announced the signing of a definitive merger agreement under which Otsuka will acquire Astex for $8.50 per share in cash.  The transaction is expected to close in the fourth quarter of 2013.

Is the Merger Best for Astex and Its Shareholders?

Robbins LLP's investigation focuses on whether the board of directors at Astex is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in the merger.  As an initial matter, the $8.50 consideration represents a premium of only 27.25% based on the Astex's closing price on September 3, 2013.  That premium is substantially below the average one-day premium of 53.13% for comparable transactions in the last three years.  Moreover, as recently as July 19, 2013, an analyst at Brean Capital, LLC set a target price of $13.00 per share, and an analyst at RBC Capital Markets set a target price of $9.00 per share on April 4, 2013.

In addition, Astex's board of directors agreed to provide additional compensation to certain company executive officers subject to consummation of the merger.  This executive compensation includes a $2 million payment to Chairman of the Board and Chief Financial Officer, James Manuso; and a $253,440 payment to Astex's Chief Medical Officer, Mohammad Azab.

Given these facts, Robbins is examining Astex's board of directors' decision to sell the company to Otsuka now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects, and whether they are seeking to benefit themselves.

Astex shareholders have the option to file a class action lawsuit to secure the best possible price for shareholders and the disclosure of material information so shareholders can vote on the transaction in an informed manner.

Astex shareholders who would like more information about their rights and potential remedies can complete the form below and we will contact you directly.  You can also contact attorney Darnell R. Donahue at (800) 350-6003.